alternatives to glp-1 medications for weight loss FDA approves Foundayo, an oral alternative Wegovy and Ozempic How To Access Weight Loss
Description
The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.
:max_bytes(150000):strip_icc()/Health-GettyImages-2112991427-c2c4d692054b4ff6933f01fc6c5be06c.jpg)
Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

Learn how to switch from tirzepatide to retatrutide safely
